ClinicalTrials.Veeva

Menu
A

Avanza Medical Research Center | Gulf Coast Office Center

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Galcanezumab
BMS-986278
LY573144
Lasmiditan
Baloxavir Marboxil
SAR440340
GFB-887
Reloxaliase
Iron
Obeldesivir

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 21 total trials

A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2)

The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of m...

Enrolling
Migraine
Drug: Lasmiditan

ACT18018 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 study with 3 treatment groups. The purpose of this...

Enrolling
Bronchiectasis
Drug: Placebo
Drug: Itepekimab (SAR440340)

The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participant...

Enrolling
Chronic Migraine
Drug: Placebo
Drug: Galcanezumab

The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatme...

Enrolling
Episodic Migraine
Drug: Galcanezumab
Drug: Placebo

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks an...

Enrolling
Migraine
Drug: Placebo
Drug: Lasmiditan
Locations recently updated

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.

Enrolling
Idiopathic Pulmonary Fibrosis
Drug: BMS-986278 Placebo
Drug: BMS-986278
Locations recently updated

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.

Enrolling
Progressive Pulmonary Fibrosis
Drug: BMS-986278 Placebo
Drug: BMS-986278

The purpose of this study is to evaluate the pre-treatment and single-dose post treatment susceptibility of baloxavir marboxil in participants aged 1...

Enrolling
Influenza
Drug: Baloxavir Marboxil

The purpose of this clinical trial (NCT02627196) is to develop valid scientific evidence for safety and effectiveness of Baroreflex Activation Therap...

Active, not recruiting
Heart Failure
Device: BAROSTIM NEO® System
Drug: Medical Management

Primary Objective:Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in...

Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Itepekimab SAR440340

Trial sponsors

Lilly logo
Bristol-Myers Squibb (BMS) logo
Roche logo
Sanofi logo
A
American Regent logo
B
B
C
Gilead Sciences logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems